Effects of TRE With Lactobacillus Plantarum LP-KFY04 Supplementation on Overweight / Obese Individuals (TRELO)
Effects of Time-Restricted Eating With Lactobacillus Plantarum LP-KFY04 Supplementation on Overweight / Obese Individuals : A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Hong Chen, MD
- Phone Number: 13602759769
- Email: rubychq@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Recruiting
- ZhuJiang Hospital of Southern Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men or women aged 18 to 65 years old
- BMI 24.0 to 40kg/m2
- Patients who are aware of the purpose of the trail, willing to participate in the trial and sign informed consent forms, and comply with all requirements (including those during follow-up and evaluation investigations)
Exclusion Criteria:
- History of HIV, hepatitis B or C (self-report) or active pulmonary tuberculosis;
- Diagnosis of type 1 or type 2 diabetes and prescribing hypoglycemic therapy
- History of malignant tumors
- Serious liver dysfunction or chronic kidney disease (aspartate aminotransferase (AST) or alanine transaminase (ALT) > 3 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m2)
- History of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction, or stroke) within the past 6 months
- History of serious gastrointestinal disease or gastrointestinal surgery within the past 12 months
- History of Cushing's syndrome, hypothyroidism, acromegaly, and hypothalamic obesity
- Smoking or have smoked within the past 3 months of the screening period
- Drinking alcohol or drinking more than 15 grams of alcohol per day within the past 3 months of the screening period
- Taking any medicine that may affect weight or metabolism within the past 6 months, including weight loss medications, antipsychotics, or other medications identified by the researchers
- Currently involving in a weight loss program or having significant weight change within the past 3 months (> 5% of current weight)
- Women who are pregnant or planning for pregnant
- Patients who are unable to complete 12-week follow-up (due to health conditions or immigration reasons)
- Patients who are unwilling or unable to provide informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Lactobacillus plantarum LP-KFY04
Patients in the treatment group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of Lactobacillus plantarum LP-KFY04 over 12 weeks' trial.
|
Patients in the treatment group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of Lactobacillus plantarum LP-KFY04 over 12 weeks' trial.
|
|
Placebo Comparator: placebo
Patients in the control group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of placebo over 12 weeks' trial.
|
Patients in the control group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of placebo over 12 weeks'trial.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change of body weight from baseline to 12 weeks after intervention
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes of BMI compared with baseline in subjects
Time Frame: 12 weeks
|
12 weeks
|
|
|
Changes of waist circumference compared with baseline in subjects
Time Frame: 12 weeks
|
12 weeks
|
|
|
Changes of body fat percentage (BF%) compared with baseline assessed by dual-energy X-ray absorptiometry (DEXA)
Time Frame: 12 weeks
|
12 weeks
|
|
|
Change of subjects' HOMA-IR compared with baseline
Time Frame: 12 weeks
|
12 weeks
|
|
|
Changes of blood pressure in subjects compared with baseline
Time Frame: 12 weeks
|
12 weeks
|
|
|
Changes of blood glucose in subjects compared with baseline
Time Frame: 12 weeks
|
12 weeks
|
|
|
Changes of blood lipids in subjects compared with baseline
Time Frame: 12 weeks
|
Blood lipids includes total cholesterol、triglyceride、LDL-c、HDL-c.
|
12 weeks
|
|
Changes of intestinal microbial composition compared with baseline in subjects
Time Frame: 12 weeks
|
Species of intestinal microbial includes Firmicutes、Bacteroidetes、Proteobacteria、Actinobacteriota、Verrucomicrobia、Fusobacteria.
|
12 weeks
|
|
Changes of intestinal microbial abundance compared with baseline in subjects
Time Frame: 12 weeks
|
Proportion of intestinal microbial such as Firmicutes、Bacteroidetes、Proteobacteria、Actinobacteriota、Verrucomicrobia、Fusobacteria
|
12 weeks
|
|
Changes of plasma metabolite compared with baseline in subjects
Time Frame: 12 weeks
|
Plasma metabolite includes arachidonic acid 、betaine、glutathione and so on.
|
12 weeks
|
|
The incidence of adverse events in two groups of subjects
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Hong Chen, MD, Zhujiang Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2024LX0016_GY
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.